-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, CSPC announced that with a down payment of 100 million yuan, and a development milestone payment, sales milestone payment and sales commission of up to 100 million yuan, it has obtained the exclusive authorization to develop the innovative drug CM326 under Connoa in several respiratory diseases.
And commercialization rights
.
This also means that CSPC's layout in the field of innovative drugs has achieved another success
.
CSPC has been "chopping hands without stopping", and has made 4 shots during the year, involving more than 1 billion yuan of "chopping hands" funds
.
Among them, this year the company has had many transactions with Connoa.
In March, Sinopharm partnered with Connoa for the exclusive authorized development and commercialization of the CM310 project in respiratory diseases such as moderate to severe asthma, and the total transaction amount was as high as 170 million yuan.
.
CM310 is a domestic first clinical trial application and obtain SFDA approval of IL-4Rα antibody for the treatment of atopic dermatitis, asthma, chronic sinusitis and nasal polyps, chronic obstructive pulmonary disease and so on
.
From the data, it can be seen that CSPC started from raw materials, but the company began to transform into innovative drugs very early.
At present, the main income comes from patent medicines, raw materials, and functional foods.
Among them, the patent medicine business includes anti-tumor, neuropsychiatric, metabolic, and Six major areas, including anti-infection, cardiovascular, immune and respiratory, contributed nearly 80% of revenue
.
Financial data shows that in the past three years, the growth rate of CSPC's patent medicine business revenue has been declining, from a growth rate of 45.
5% in 2018 to 6.
8% in the three quarters of this year
.
This is inseparable from the influence of medical insurance negotiations and centralized procurement policies.
In the first four purchases with volume, CSPC won the bid for 18 products, including albumin paclitaxel and other large varieties of 1 billion
.
Although the product can gain market volume after winning the bid, the short-term performance is still under pressure due to the significant drop in the price of the winning bid
.
Taking CSPC’s blockbuster product Enbipu as an example, the product was successfully included in the 2020 medical insurance negotiations through an average reduction of 52%, and its sales in 2020 were 6.
5 billion yuan, accounting for 26% of the overall revenue
.
However, after entering the medical insurance negotiations, the third quarter report of this year showed that Enbipu’s sales revenue decreased by 11.
2% year-on-year
.
On November 18, CSPC’s 2021 third quarter report revealed that in the first three quarters of this year, CSPC’s revenue was 20.
64 billion yuan, a year-on-year increase of 7.
4%; net profit reached 4.
335 billion yuan, an increase of 23.
2%
.
From the perspective of the reasons for the performance growth in the first three quarters, innovative drugs have contributed a lot
.
In the first three quarters, anti-tumor drugs contributed 5.
778 billion yuan in revenue, becoming a major source of revenue, exceeding sales of 5.
505 billion yuan in neurological drugs
.
It can be said that innovative drugs have brought "sweetness" to the performance of CSPC, and the company has repeatedly "chopped hands" to increase the field of innovative drugs and become traceable
.
Previously, the chairman of CSPC has stated to the outside that the entire pharmaceutical industry is splitting up at two levels, and the adjustment of medical insurance access policies and the introduction of centralized procurement policies are accelerating the elimination of backward companies
.
He believes that the only way to save traditional pharmaceutical companies is to take innovation
.
How to innovate? Competent companies can build a team to do it on their own, and buy what can't be done.
They can use CRO (R&D outsourcing) to do clinical work, and get some competitive products approved
.
In recent years, CSPC has mainly used self-research and introduction of two-legged walking
.
In terms of introduction, the company focuses on the layout.
As for the popular innovative macromolecular drugs, of the company's 4 macromolecular drugs that have entered clinical phase III, three are imported products
.
Although CSPC has not yet successfully promoted the introduction of products on the market, in the 2020 annual report, CSPC also mentioned the need to improve R&D and innovation capabilities and efficiency
.
Previously, media reports stated that in order to promote BD cooperation, CSPC reorganized its business development department.
The team introduced talents from many large multinational pharmaceutical companies to join.
In 5 months, the department evaluated more than 110 projects, including tumor/ There are up to 60 immuno-oncology programs, 6 stroke/central nervous system programs, and 12 respiratory programs
.
It can be seen that CSPC is making great efforts to promote the implementation of products.
The introduction of products this year will also enrich the company's product line under research and help accelerate the pace of company transformation
.
And commercialization rights
.
This also means that CSPC's layout in the field of innovative drugs has achieved another success
.
CSPC has been "chopping hands without stopping", and has made 4 shots during the year, involving more than 1 billion yuan of "chopping hands" funds
.
Among them, this year the company has had many transactions with Connoa.
In March, Sinopharm partnered with Connoa for the exclusive authorized development and commercialization of the CM310 project in respiratory diseases such as moderate to severe asthma, and the total transaction amount was as high as 170 million yuan.
.
CM310 is a domestic first clinical trial application and obtain SFDA approval of IL-4Rα antibody for the treatment of atopic dermatitis, asthma, chronic sinusitis and nasal polyps, chronic obstructive pulmonary disease and so on
.
From the data, it can be seen that CSPC started from raw materials, but the company began to transform into innovative drugs very early.
At present, the main income comes from patent medicines, raw materials, and functional foods.
Among them, the patent medicine business includes anti-tumor, neuropsychiatric, metabolic, and Six major areas, including anti-infection, cardiovascular, immune and respiratory, contributed nearly 80% of revenue
.
Financial data shows that in the past three years, the growth rate of CSPC's patent medicine business revenue has been declining, from a growth rate of 45.
5% in 2018 to 6.
8% in the three quarters of this year
.
This is inseparable from the influence of medical insurance negotiations and centralized procurement policies.
In the first four purchases with volume, CSPC won the bid for 18 products, including albumin paclitaxel and other large varieties of 1 billion
.
Although the product can gain market volume after winning the bid, the short-term performance is still under pressure due to the significant drop in the price of the winning bid
.
Taking CSPC’s blockbuster product Enbipu as an example, the product was successfully included in the 2020 medical insurance negotiations through an average reduction of 52%, and its sales in 2020 were 6.
5 billion yuan, accounting for 26% of the overall revenue
.
However, after entering the medical insurance negotiations, the third quarter report of this year showed that Enbipu’s sales revenue decreased by 11.
2% year-on-year
.
On November 18, CSPC’s 2021 third quarter report revealed that in the first three quarters of this year, CSPC’s revenue was 20.
64 billion yuan, a year-on-year increase of 7.
4%; net profit reached 4.
335 billion yuan, an increase of 23.
2%
.
From the perspective of the reasons for the performance growth in the first three quarters, innovative drugs have contributed a lot
.
In the first three quarters, anti-tumor drugs contributed 5.
778 billion yuan in revenue, becoming a major source of revenue, exceeding sales of 5.
505 billion yuan in neurological drugs
.
It can be said that innovative drugs have brought "sweetness" to the performance of CSPC, and the company has repeatedly "chopped hands" to increase the field of innovative drugs and become traceable
.
Previously, the chairman of CSPC has stated to the outside that the entire pharmaceutical industry is splitting up at two levels, and the adjustment of medical insurance access policies and the introduction of centralized procurement policies are accelerating the elimination of backward companies
.
He believes that the only way to save traditional pharmaceutical companies is to take innovation
.
How to innovate? Competent companies can build a team to do it on their own, and buy what can't be done.
They can use CRO (R&D outsourcing) to do clinical work, and get some competitive products approved
.
In recent years, CSPC has mainly used self-research and introduction of two-legged walking
.
In terms of introduction, the company focuses on the layout.
As for the popular innovative macromolecular drugs, of the company's 4 macromolecular drugs that have entered clinical phase III, three are imported products
.
Although CSPC has not yet successfully promoted the introduction of products on the market, in the 2020 annual report, CSPC also mentioned the need to improve R&D and innovation capabilities and efficiency
.
Previously, media reports stated that in order to promote BD cooperation, CSPC reorganized its business development department.
The team introduced talents from many large multinational pharmaceutical companies to join.
In 5 months, the department evaluated more than 110 projects, including tumor/ There are up to 60 immuno-oncology programs, 6 stroke/central nervous system programs, and 12 respiratory programs
.
It can be seen that CSPC is making great efforts to promote the implementation of products.
The introduction of products this year will also enrich the company's product line under research and help accelerate the pace of company transformation
.
